test 3

Pharmacodynamics: Agonists, Antagonists, and Drug Interactions

Main Takeaway

Pharmacodynamics studies what drugs do to the body, focusing on their interactions with molecular targets. Agonists elicit responses by mimicking endogenous molecules, while antagonists inhibit responses. Understanding their binding characteristics, efficacy, and potency is crucial for evaluating therapeutic benefit and toxicity, especially through analyzing full concentration-response curves.

1. Pharmacodynamics Overview

• Concentration Occupancy vs. Concentration Response:

• Concentration occupancy curve: Measures affinity (e.g., via radiolabelling, fluorescence imaging).

• Concentration response curve: Measures the observed effect, a consequence of binding.

• These are not linearly related.

• Agonists:

• Elicit a response.

• Full vs. Partial Agonists: Differentiated by their ability to activate, governed by efficacy.

• Mimic endogenous signalling molecules.

• Antagonists:

• Unable to elicit a response on their own.

• Can be effective therapeutic agents by inhibiting endogenous signalling molecules.

• Key Concepts:

• Efficacy: The ability of a drug to activate a receptor and elicit a maximum response.

• Potency: The concentration of a drug required to elicit a response.

2. Competitive Antagonism

• Definition: Antagonist and agonist bind to the same active site, meaning only one drug can bind at a time.

• Mechanism: Antagonist binding prevents agonist binding, thereby stopping the agonist's effect.

• Measurement:

• Agonist responses are measured first, then re-measured after incubation with the antagonist.

• Observation: A parallel rightward shift of the agonist concentration-response curve.

• At low agonist concentrations, the response can be abolished.

• At high agonist concentrations, the effect of the antagonist can be overcome.

• Effect: The agonist appears less potent (more agonist is needed for the same effect), but its maximum efficacy is unaffected.

• Characteristics: This interaction is reversible and the effect of the antagonist is surmountable (can be overcome by increasing agonist concentration).

• Governed by: The Law of Mass Action (governs drug-receptor binding properties, ensuring equilibrium).

2.1 Quantifying Antagonist Potency

• $K_D$ (Dissociation Constant) / $K_B$ (for Antagonists):

• Can be derived from direct binding assays at molecular/cellular levels.

• Requires radioactively or fluorescently labelled molecules.

• Functional Level Measurement:

• $pA_2$: The negative logarithm of the concentration of antagonist required to cause a twofold rightward shift of the agonist concentration curve.

• Approximates $pK_B$ in purely displacement, Law of Mass Action scenarios.

• Shield Plot: An analytical approach involving multiple concentration-response curves with increasing antagonist concentrations.

• Plot $\log(\text{dose ratio} - 1)$ versus $\log(\text{concentration of B (antagonist)})$.

• A linear plot with a slope of 1 indicates competitive antagonism and can provide an indication of the $K_B$.

• A slope $\ne$ 1 suggests a non-competitive interaction.

2.2 Partial Agonists as Antagonists

• Partial agonists with low intrinsic activity can act as antagonists.

• Mechanism: They occupy receptors, eliciting a sub-maximal response themselves, but prevent full agonists from binding.

• Effect:

• Initially, there might be an additive effect with endogenous agonists.

• Once partial agonists occupy most receptors, they behave like classic competitive antagonists, causing a rightward shift of the full agonist's concentration-response curve.

3. Non-Competitive Antagonism & Irreversible Antagonism

• Characteristics:

• Depression of the maximum response (maximal efficacy is reduced).

• A rightward shift, but the shift is not parallel.

• A Shield plot of this data would yield a slope $\ne$ 1.

• Causes:

• High-affinity competitive antagonists: Those with slow dissociation constants can effectively "look" irreversible, removing a proportion of available receptors, leading to a depression of the maximal response.

• Non-competitive inhibitors: Act at a site distinct from the agonist's binding site.

4. Mechanisms of Non-Competitive Interactions

Drugs can interfere with effects at various stages beyond simple receptor competition:

• Chemical Antagonists:

• Inactivate molecules before they reach their receptor.

• Example: Antibodies used in anti-cancer chemotherapies or anti-asthma therapies that target and inactivate a chemical ligand.

• Allosteric Modulation:

• Act at the same molecular target (receptor) but at a different binding site.

• Changes the affinity or activation state of the molecular target.

• Pathway Inhibition:

• Inhibit components of the signaling pathway downstream or upstream of the primary receptor target.

• Targets can include enzymes or ion channels.

• Example: Noradrenaline increases heart rate by acting on $\beta_1$ adrenoreceptors, activating G proteins, adenylate cyclase, cAMP, protein kinases, and L-type calcium channels, leading to calcium influx.

• Potential targets: Receptor, enzyme (adenylate cyclase), ion channel (L-type calcium channel).

• Verapamil blocks the L-type calcium channel, acting as an antagonist in cardiac conditions, useful when $\beta$-blockers are contraindicated.

• Functional Antagonists:

• Two agonists act on different receptors to produce equal and opposite effects at the same site.

• Example: Acetylcholine decreases heart rate, while noradrenaline increases heart rate.

5. Clinical Efficacy and Therapeutic Window

• Goal: Optimize clinical efficacy (benefit) and minimize clinical toxicity.

• Molecular Level Considerations:

• The relative affinity for molecular targets.

• Efficacy of interaction at target.

• Desired vs. Undesired Effects:

• Narrow Therapeutic Window:

• The same molecular target produces both the desired therapeutic effect and an undesired toxic effect.

• Affinity and efficacy for this target are identical.

• Example: A drug that increases cardiac contractility can cause dysrhythmia if the effect is too large.

• Different Therapeutic and Toxic Mechanisms:

• Therapeutic effect at one target (high affinity) and toxic effect at a different target (lower affinity, but becomes significant at higher concentrations).

• Example: Pain relief drugs with high affinity for intended target, but at higher concentrations, can cause liver damage by interacting with other targets.

• Conclusion: The usable dose of a drug is constrained by unwanted actions. The relative affinity for different targets (pharmacodynamic perspective) and pharmacokinetics influence the dose-response relationship and the overall benefit-risk profile.

6. Summary of Pharmacodynamic Principles

• What drugs do: Pharmacodynamics.

• Binding:

• Agonists and antagonists have affinity for specific molecular targets.

• Relative affinity determines selectivity.

• Agonists:

• "Make things happen."

• Can be full or partial due to varying efficacy (ability to activate stimulus-response mechanism).

• Efficacy influences potency (amount of drug for a given response).

• Antagonists:

• Can be competitive (same site) or non-competitive (different sites).

• Have no intrinsic efficacy at the molecular/organ bath level.

• Have clinical efficacy by inhibiting overactive endogenous systems.

• Potency is defined by the amount required to inhibit agonist binding/responses.

• Key takeaway: Concentration-response relationships are crucial. Always examine the full concentration-response range, as effects of single concentrations can be misleading.